Enterprise Value

356.6B

Cash

5.619B

Avg Qtr Burn

N/A

Short % of Float

0.80%

Insider Ownership

0.05%

Institutional Own.

78.85%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Update

KEYTRUDA Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Update

GARDASIL 9 Details
Human Papillomavirus 9-valent Vaccine, Human papillomavirus

Approved

Update

Approved

Update

KEYTRUDA+ trastuzumab+ chemotherapy Details
Cancer, Gastroesophageal adenocarcinomas, Gastric cancer

Approved

Quarterly sales

LYNPARZA(olaparib) + abi/pred Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Approved

Quarterly sales

Approved

Quarterly sales

WINREVAIR (sotatercept-csrk) Details
Pulmonary arterial hypertension

Approved

Quarterly sales

KEYTRUDA+ chemotherapy Details
Cancer, Biliary Tract Cancer

Approved

Quarterly sales

PREVYMIS™ (letermovir) Details
Cytomegalovirus, Viral infection

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

KEYTRUDA in comb w/chemotherapy Details
Non-small cell lung carcinoma, Solid tumor/s, Cancer

Approved

Quarterly sales

Approved

Quarterly sales

KEYTRUDA + chemotherapy Details
Cancer, Gastroesophageal adenocarcinomas, Gastric cancer

Approved

Quarterly sales

TUKYSA (Tucatinib) Details
Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer

Approved

Quarterly sales

KEYTRUDA+ chemotherapy Details
Cancer, Mesothelioma, Malignant pleural/peritoneal mesothelioma

PDUFA

Approval decision

Patritumab deruxtecan (HER3-DXd) Details
Non-small cell lung carcinoma

PDUFA

Approval decision

KEYTRUDA +carboplatin + paclitaxel Details
Cancer, Solid tumor/s, Carcinoma , Endometrial cancer

PDUFA

Approval decision

V116 Details
Pneumococcal Conjugate Vaccine

PDUFA

Approval decision

NDA

FDA meeting

MK-2870 Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Nemtabrutinib Details
Cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia

Phase 3

Data readout

MK-5684 (ODM-208) Details
Cancer, Castration-resistant prostate cancer

Phase 3

Data readout

Bomedemstat Details
Thrombocythemia

Phase 3

Data readout

MK-0616 Details
Cardiovascular disease , Hypercholesterolemia

Phase 3

Data readout

KEYTRUDA+pemetrexed Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

MK-1084 +KEYTRUDA® Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

LAGEVRIO™ (molnupiravir) Details
Viral infection, COVID-19

Phase 3

Data readout

Islatravir+ Doravirine Details
Viral infection, Human immunodeficiency virus

Phase 3

Data readout

KEYTRUDA +LENVIMA® (lenvatinib) Details
Cancer, Non-small cell lung carcinoma

Phase 3

Update

KEYTRUDA Details
Cancer, Renal cell carcinoma

Phase 3

Update

Phase 3

Update

KEYTRUDA + LENVIMA Details
Cancer, Renal cell carcinoma

Phase 3

Update

KEYTRUDA +LENVIMA® (lenvatinib) Details
Cancer, Carcinoma , Endometrial cancer

Phase 3

Update

KEYTRUDA Details
Cancer, Solid tumor/s, ER+/HER2- breast cancer

Phase 3

Update

KEYTRUDA Details
Cancer, Solid tumor/s, Urothelial carcinoma

Phase 3

Update

KEYTRUDA Details
Solid tumor/s, Cancer, Triple-negative breast cancer , Breast cancer

Phase 3

Update

Phase 3

Initiation

MK-0616 Details
Hypercholesterolemia

Phase 3

Initiation

Raludotatug Deruxtecan Details
Platinum-resistant ovarian cancer, Cancer

Phase 2/3

Data readout

Efinopegdutide (MK-6024) Details
Non-Alcoholic Fatty Liver Disease, Liver disease

Phase 2b

Initiation

Phase 2

Data readout

PRA023 (Anti-TL1A mAb) Details
Autoimmune disease, Systemic sclerosis

Phase 2

Data readout

PRA023 (Anti-TL1A mAb) Details
Systemic sclerosis, Autoimmune disease

Phase 2

Data readout

MK-7240 (PRA023) (Anti-TL1A mAb) Details
Irritable bowel syndrome, Crohns disease, Ulcerative colitis

Phase 2

Update

Belzutifan + cabozantinib Details
Cancer, Renal cell carcinoma

Phase 2

Update

HPN328 (DLL3) +/- atezolizumab Details
Solid tumor/s, Cancer, Small cell lung cancer

Phase 1/2

Data readout

HPN217 (BCMA) Details
Multiple myeloma

Phase 1

Update

PRA052 Details
Inflammatory bowel disease

Phase 1

Update

KEYTRUDA + LENVIMA Details
Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued

KEYTRUDA+ enzalutamide + androgen deprivation therapy (ADT) Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Failed

Discontinued